The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ustekinumab Market Research Report 2024
Synopsis
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
The global Ustekinumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Ustekinumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ustekinumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Ustekinumab include Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ustekinumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ustekinumab.
Report Scope
The Ustekinumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ustekinumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ustekinumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Outlook Therapeutics
Harvest Moon Pharma
BioXpress
Segment by Type
Intravenous
Subcutaneous
Segment by Application
Arthritis
Colitis
Lupus Erythematosus
Myositis Multiplex With Palmoplantar Pustulosis
Cirrhosis Of The Liver
Sarcoidosis
Diabetes
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ustekinumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ustekinumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
The global Ustekinumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Ustekinumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ustekinumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Ustekinumab include Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ustekinumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ustekinumab.
Report Scope
The Ustekinumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ustekinumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ustekinumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Outlook Therapeutics
Harvest Moon Pharma
BioXpress
Segment by Type
Intravenous
Subcutaneous
Segment by Application
Arthritis
Colitis
Lupus Erythematosus
Myositis Multiplex With Palmoplantar Pustulosis
Cirrhosis Of The Liver
Sarcoidosis
Diabetes
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ustekinumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ustekinumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Ustekinumab Market Overview
1.1 Product Overview and Scope of Ustekinumab
1.2 Ustekinumab Segment by Type
1.2.1 Global Ustekinumab Market Value Comparison by Type (2024-2030)
1.2.2 Intravenous
1.2.3 Subcutaneous
1.3 Ustekinumab Segment by Application
1.3.1 Global Ustekinumab Market Value by Application: (2024-2030)
1.3.2 Arthritis
1.3.3 Colitis
1.3.4 Lupus Erythematosus
1.3.5 Myositis Multiplex With Palmoplantar Pustulosis
1.3.6 Cirrhosis Of The Liver
1.3.7 Sarcoidosis
1.3.8 Diabetes
1.3.9 Other
1.4 Global Ustekinumab Market Size Estimates and Forecasts
1.4.1 Global Ustekinumab Revenue 2019-2030
1.4.2 Global Ustekinumab Sales 2019-2030
1.4.3 Global Ustekinumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Ustekinumab Market Competition by Manufacturers
2.1 Global Ustekinumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Ustekinumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Ustekinumab Average Price by Manufacturers (2019-2024)
2.4 Global Ustekinumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ustekinumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ustekinumab, Product Type & Application
2.7 Ustekinumab Market Competitive Situation and Trends
2.7.1 Ustekinumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ustekinumab Players Market Share by Revenue
2.7.3 Global Ustekinumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ustekinumab Retrospective Market Scenario by Region
3.1 Global Ustekinumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Ustekinumab Global Ustekinumab Sales by Region: 2019-2030
3.2.1 Global Ustekinumab Sales by Region: 2019-2024
3.2.2 Global Ustekinumab Sales by Region: 2025-2030
3.3 Global Ustekinumab Global Ustekinumab Revenue by Region: 2019-2030
3.3.1 Global Ustekinumab Revenue by Region: 2019-2024
3.3.2 Global Ustekinumab Revenue by Region: 2025-2030
3.4 North America Ustekinumab Market Facts & Figures by Country
3.4.1 North America Ustekinumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Ustekinumab Sales by Country (2019-2030)
3.4.3 North America Ustekinumab Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ustekinumab Market Facts & Figures by Country
3.5.1 Europe Ustekinumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Ustekinumab Sales by Country (2019-2030)
3.5.3 Europe Ustekinumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ustekinumab Market Facts & Figures by Country
3.6.1 Asia Pacific Ustekinumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Ustekinumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Ustekinumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ustekinumab Market Facts & Figures by Country
3.7.1 Latin America Ustekinumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Ustekinumab Sales by Country (2019-2030)
3.7.3 Latin America Ustekinumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ustekinumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Ustekinumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Ustekinumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Ustekinumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ustekinumab Sales by Type (2019-2030)
4.1.1 Global Ustekinumab Sales by Type (2019-2024)
4.1.2 Global Ustekinumab Sales by Type (2025-2030)
4.1.3 Global Ustekinumab Sales Market Share by Type (2019-2030)
4.2 Global Ustekinumab Revenue by Type (2019-2030)
4.2.1 Global Ustekinumab Revenue by Type (2019-2024)
4.2.2 Global Ustekinumab Revenue by Type (2025-2030)
4.2.3 Global Ustekinumab Revenue Market Share by Type (2019-2030)
4.3 Global Ustekinumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Ustekinumab Sales by Application (2019-2030)
5.1.1 Global Ustekinumab Sales by Application (2019-2024)
5.1.2 Global Ustekinumab Sales by Application (2025-2030)
5.1.3 Global Ustekinumab Sales Market Share by Application (2019-2030)
5.2 Global Ustekinumab Revenue by Application (2019-2030)
5.2.1 Global Ustekinumab Revenue by Application (2019-2024)
5.2.2 Global Ustekinumab Revenue by Application (2025-2030)
5.2.3 Global Ustekinumab Revenue Market Share by Application (2019-2030)
5.3 Global Ustekinumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Meiji
6.1.1 Meiji Corporation Information
6.1.2 Meiji Description and Business Overview
6.1.3 Meiji Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Meiji Ustekinumab Product Portfolio
6.1.5 Meiji Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Ustekinumab Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Alvotech
6.3.1 Alvotech Corporation Information
6.3.2 Alvotech Description and Business Overview
6.3.3 Alvotech Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Alvotech Ustekinumab Product Portfolio
6.3.5 Alvotech Recent Developments/Updates
6.4 Fuji Pharma
6.4.1 Fuji Pharma Corporation Information
6.4.2 Fuji Pharma Description and Business Overview
6.4.3 Fuji Pharma Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Fuji Pharma Ustekinumab Product Portfolio
6.4.5 Fuji Pharma Recent Developments/Updates
6.5 Mitsubishi Tanabe
6.5.1 Mitsubishi Tanabe Corporation Information
6.5.2 Mitsubishi Tanabe Description and Business Overview
6.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mitsubishi Tanabe Ustekinumab Product Portfolio
6.5.5 Mitsubishi Tanabe Recent Developments/Updates
6.6 Stada
6.6.1 Stada Corporation Information
6.6.2 Stada Description and Business Overview
6.6.3 Stada Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Stada Ustekinumab Product Portfolio
6.6.5 Stada Recent Developments/Updates
6.7 EPIRUS BioPharma
6.6.1 EPIRUS BioPharma Corporation Information
6.6.2 EPIRUS BioPharma Description and Business Overview
6.6.3 EPIRUS BioPharma Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 EPIRUS BioPharma Ustekinumab Product Portfolio
6.7.5 EPIRUS BioPharma Recent Developments/Updates
6.8 Formycon
6.8.1 Formycon Corporation Information
6.8.2 Formycon Description and Business Overview
6.8.3 Formycon Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Formycon Ustekinumab Product Portfolio
6.8.5 Formycon Recent Developments/Updates
6.9 NeuClone
6.9.1 NeuClone Corporation Information
6.9.2 NeuClone Description and Business Overview
6.9.3 NeuClone Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.9.4 NeuClone Ustekinumab Product Portfolio
6.9.5 NeuClone Recent Developments/Updates
6.10 Outlook Therapeutics
6.10.1 Outlook Therapeutics Corporation Information
6.10.2 Outlook Therapeutics Description and Business Overview
6.10.3 Outlook Therapeutics Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Outlook Therapeutics Ustekinumab Product Portfolio
6.10.5 Outlook Therapeutics Recent Developments/Updates
6.11 Harvest Moon Pharma
6.11.1 Harvest Moon Pharma Corporation Information
6.11.2 Harvest Moon Pharma Ustekinumab Description and Business Overview
6.11.3 Harvest Moon Pharma Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Harvest Moon Pharma Ustekinumab Product Portfolio
6.11.5 Harvest Moon Pharma Recent Developments/Updates
6.12 BioXpress
6.12.1 BioXpress Corporation Information
6.12.2 BioXpress Ustekinumab Description and Business Overview
6.12.3 BioXpress Ustekinumab Sales, Revenue and Gross Margin (2019-2024)
6.12.4 BioXpress Ustekinumab Product Portfolio
6.12.5 BioXpress Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ustekinumab Industry Chain Analysis
7.2 Ustekinumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ustekinumab Production Mode & Process
7.4 Ustekinumab Sales and Marketing
7.4.1 Ustekinumab Sales Channels
7.4.2 Ustekinumab Distributors
7.5 Ustekinumab Customers
8 Ustekinumab Market Dynamics
8.1 Ustekinumab Industry Trends
8.2 Ustekinumab Market Drivers
8.3 Ustekinumab Market Challenges
8.4 Ustekinumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Ustekinumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Ustekinumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Ustekinumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Ustekinumab Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Ustekinumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Ustekinumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Ustekinumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Ustekinumab Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Ustekinumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Ustekinumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Ustekinumab, Product Type & Application
Table 12. Global Key Manufacturers of Ustekinumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Ustekinumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ustekinumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Ustekinumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Ustekinumab Sales by Region (2019-2024) & (K Units)
Table 18. Global Ustekinumab Sales Market Share by Region (2019-2024)
Table 19. Global Ustekinumab Sales by Region (2025-2030) & (K Units)
Table 20. Global Ustekinumab Sales Market Share by Region (2025-2030)
Table 21. Global Ustekinumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Ustekinumab Revenue Market Share by Region (2019-2024)
Table 23. Global Ustekinumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Ustekinumab Revenue Market Share by Region (2025-2030)
Table 25. North America Ustekinumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Ustekinumab Sales by Country (2019-2024) & (K Units)
Table 27. North America Ustekinumab Sales by Country (2025-2030) & (K Units)
Table 28. North America Ustekinumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Ustekinumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Ustekinumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Ustekinumab Sales by Country (2019-2024) & (K Units)
Table 32. Europe Ustekinumab Sales by Country (2025-2030) & (K Units)
Table 33. Europe Ustekinumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Ustekinumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Ustekinumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Ustekinumab Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Ustekinumab Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Ustekinumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Ustekinumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Ustekinumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Ustekinumab Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Ustekinumab Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Ustekinumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Ustekinumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Ustekinumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Ustekinumab Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Ustekinumab Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Ustekinumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Ustekinumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Ustekinumab Sales (K Units) by Type (2019-2024)
Table 51. Global Ustekinumab Sales (K Units) by Type (2025-2030)
Table 52. Global Ustekinumab Sales Market Share by Type (2019-2024)
Table 53. Global Ustekinumab Sales Market Share by Type (2025-2030)
Table 54. Global Ustekinumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Ustekinumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Ustekinumab Revenue Market Share by Type (2019-2024)
Table 57. Global Ustekinumab Revenue Market Share by Type (2025-2030)
Table 58. Global Ustekinumab Price (US$/Unit) by Type (2019-2024)
Table 59. Global Ustekinumab Price (US$/Unit) by Type (2025-2030)
Table 60. Global Ustekinumab Sales (K Units) by Application (2019-2024)
Table 61. Global Ustekinumab Sales (K Units) by Application (2025-2030)
Table 62. Global Ustekinumab Sales Market Share by Application (2019-2024)
Table 63. Global Ustekinumab Sales Market Share by Application (2025-2030)
Table 64. Global Ustekinumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Ustekinumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Ustekinumab Revenue Market Share by Application (2019-2024)
Table 67. Global Ustekinumab Revenue Market Share by Application (2025-2030)
Table 68. Global Ustekinumab Price (US$/Unit) by Application (2019-2024)
Table 69. Global Ustekinumab Price (US$/Unit) by Application (2025-2030)
Table 70. Meiji Corporation Information
Table 71. Meiji Description and Business Overview
Table 72. Meiji Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Meiji Ustekinumab Product
Table 74. Meiji Recent Developments/Updates
Table 75. Johnson & Johnson Corporation Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Johnson & Johnson Ustekinumab Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Alvotech Corporation Information
Table 81. Alvotech Description and Business Overview
Table 82. Alvotech Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Alvotech Ustekinumab Product
Table 84. Alvotech Recent Developments/Updates
Table 85. Fuji Pharma Corporation Information
Table 86. Fuji Pharma Description and Business Overview
Table 87. Fuji Pharma Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Fuji Pharma Ustekinumab Product
Table 89. Fuji Pharma Recent Developments/Updates
Table 90. Mitsubishi Tanabe Corporation Information
Table 91. Mitsubishi Tanabe Description and Business Overview
Table 92. Mitsubishi Tanabe Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Mitsubishi Tanabe Ustekinumab Product
Table 94. Mitsubishi Tanabe Recent Developments/Updates
Table 95. Stada Corporation Information
Table 96. Stada Description and Business Overview
Table 97. Stada Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Stada Ustekinumab Product
Table 99. Stada Recent Developments/Updates
Table 100. EPIRUS BioPharma Corporation Information
Table 101. EPIRUS BioPharma Description and Business Overview
Table 102. EPIRUS BioPharma Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. EPIRUS BioPharma Ustekinumab Product
Table 104. EPIRUS BioPharma Recent Developments/Updates
Table 105. Formycon Corporation Information
Table 106. Formycon Description and Business Overview
Table 107. Formycon Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Formycon Ustekinumab Product
Table 109. Formycon Recent Developments/Updates
Table 110. NeuClone Corporation Information
Table 111. NeuClone Description and Business Overview
Table 112. NeuClone Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. NeuClone Ustekinumab Product
Table 114. NeuClone Recent Developments/Updates
Table 115. Outlook Therapeutics Corporation Information
Table 116. Outlook Therapeutics Description and Business Overview
Table 117. Outlook Therapeutics Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Outlook Therapeutics Ustekinumab Product
Table 119. Outlook Therapeutics Recent Developments/Updates
Table 120. Harvest Moon Pharma Corporation Information
Table 121. Harvest Moon Pharma Description and Business Overview
Table 122. Harvest Moon Pharma Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Harvest Moon Pharma Ustekinumab Product
Table 124. Harvest Moon Pharma Recent Developments/Updates
Table 125. BioXpress Corporation Information
Table 126. BioXpress Description and Business Overview
Table 127. BioXpress Ustekinumab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. BioXpress Ustekinumab Product
Table 129. BioXpress Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Ustekinumab Distributors List
Table 133. Ustekinumab Customers List
Table 134. Ustekinumab Market Trends
Table 135. Ustekinumab Market Drivers
Table 136. Ustekinumab Market Challenges
Table 137. Ustekinumab Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Ustekinumab
Figure 2. Global Ustekinumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Ustekinumab Market Share by Type in 2023 & 2030
Figure 4. Intravenous Product Picture
Figure 5. Subcutaneous Product Picture
Figure 6. Global Ustekinumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Ustekinumab Market Share by Application in 2023 & 2030
Figure 8. Arthritis
Figure 9. Colitis
Figure 10. Lupus Erythematosus
Figure 11. Myositis Multiplex With Palmoplantar Pustulosis
Figure 12. Cirrhosis Of The Liver
Figure 13. Sarcoidosis
Figure 14. Diabetes
Figure 15. Other
Figure 16. Global Ustekinumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Ustekinumab Market Size (2019-2030) & (US$ Million)
Figure 18. Global Ustekinumab Sales (2019-2030) & (K Units)
Figure 19. Global Ustekinumab Average Price (US$/Unit) & (2019-2030)
Figure 20. Ustekinumab Report Years Considered
Figure 21. Ustekinumab Sales Share by Manufacturers in 2023
Figure 22. Global Ustekinumab Revenue Share by Manufacturers in 2023
Figure 23. The Global 5 and 10 Largest Ustekinumab Players: Market Share by Revenue in 2023
Figure 24. Ustekinumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 25. Global Ustekinumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 26. North America Ustekinumab Sales Market Share by Country (2019-2030)
Figure 27. North America Ustekinumab Revenue Market Share by Country (2019-2030)
Figure 28. U.S. Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Canada Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Europe Ustekinumab Sales Market Share by Country (2019-2030)
Figure 31. Europe Ustekinumab Revenue Market Share by Country (2019-2030)
Figure 32. Germany Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. France Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. U.K. Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Italy Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Russia Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Asia Pacific Ustekinumab Sales Market Share by Region (2019-2030)
Figure 38. Asia Pacific Ustekinumab Revenue Market Share by Region (2019-2030)
Figure 39. China Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Japan Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. South Korea Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. India Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Taiwan Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Indonesia Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Thailand Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Malaysia Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Philippines Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Latin America Ustekinumab Sales Market Share by Country (2019-2030)
Figure 50. Latin America Ustekinumab Revenue Market Share by Country (2019-2030)
Figure 51. Mexico Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Brazil Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Argentina Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Middle East & Africa Ustekinumab Sales Market Share by Country (2019-2030)
Figure 55. Middle East & Africa Ustekinumab Revenue Market Share by Country (2019-2030)
Figure 56. Turkey Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Saudi Arabia Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. UAE Ustekinumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 59. Global Sales Market Share of Ustekinumab by Type (2019-2030)
Figure 60. Global Revenue Market Share of Ustekinumab by Type (2019-2030)
Figure 61. Global Ustekinumab Price (US$/Unit) by Type (2019-2030)
Figure 62. Global Sales Market Share of Ustekinumab by Application (2019-2030)
Figure 63. Global Revenue Market Share of Ustekinumab by Application (2019-2030)
Figure 64. Global Ustekinumab Price (US$/Unit) by Application (2019-2030)
Figure 65. Ustekinumab Value Chain
Figure 66. Ustekinumab Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
